Travopine B 2 Eye Drop contains Timolol 5mg/ml + Brimonidine 2mg/ml, a dual-action anti-glaucoma ophthalmic formulation designed for effective reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension. Its precise combination ensures enhanced and sustained pressure control.
The eye drop works by reducing aqueous humor production via Timolol and decreasing aqueous formation while increasing outflow via Brimonidine, providing comprehensive intraocular pressure management and protecting the optic nerve.
From a franchise perspective, Travopine B 2 Eye Drop is a high-demand combination therapy, widely prescribed in eye hospitals, ophthalmology clinics, and glaucoma care centers, ensuring steady prescriptions, repeat orders, and strong prescriber trust.
Adding Travopine B 2 Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma combination segment, offering long-term growth, market credibility, and a competitive advantage for PCD pharma franchise partners.